Testing a new long-acting schizophrenia drug
Part of Mental health clinical trials.
This study tests a new extended-release injection for schizophrenia, comparing it to the existing drug Vraylar. It's for people who are currently stable on their antipsychotic medication and have tolerated oral cariprazine before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with schizophrenia and are currently stable on one antipsychotic medication (not cariprazine).
- You have taken and tolerated oral cariprazine at a dose of 3 mg or higher before.
- You have a body mass index (BMI) between 18.50 and 30.00, and healthy liver, kidney, and blood function.
- You agree to avoid alcohol and smoking more than 10 cigarettes per day during the study.
- You are not pregnant, breastfeeding, or planning pregnancy, and use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
This trial tests a new medication called VV119 for adults currently experiencing a sudden worsening of schizophrenia symptoms. The goal is to see if it is safe and if it helps reduce symptoms like delusions, disorganized thinking, and hallucinations.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
This is an early-stage study testing a new experimental drug called KR23248 in healthy volunteers to see if it is safe and how the body processes it. Researchers want to understand potential side effects and how the drug moves through your system.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.